Biotech Matters

Bluestar BioAdvisors team shares insights on drug pipelines and predicts industry trends. Each episode is hosted by a senior member of our New York City based life sciences consulting firm. The host is typically joined by an external expert guest, with whom the host expands on their experiences providing insights and recommendations for industry leaders and emergent innovators, and translating the data of today into the implications for business of science of tomorrow.

Biotech Matters is a science podcast hosted by Bluestar BioAdvisors, with 8 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Bluestar BioAdvisors hosts Biotech Matters, a science show with 8 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #8

  New Frontiers in FSGS: A Discussion of Recent Data and Developments (with Dr. Howard Trachtman)

  Mar 27, 202640 minS0

  <p>In this episode, Bluestar Principal Jeff Fineberg is joined by Dr. Howard Trachtman, a pediatric nephrologist and researcher, who has been a principal investigator on many NIH- and industry-sponsored clinical trials in glomerular diseases, including FSGS.</p> <p>Following a brief recap of the recent history of sparsentan in FSGS, and some recent developments in its hopeful path toward FDA approval, Jeff and Dr. Trachtman define what FSGS really is, before the two of them dive into the long-term efficacy and safety data of sparsentan in FSGS from the DUET and DUPLEX clinical trials. This includes a discussion of...

  ListenShow Notes
• 

  Episode #7

  Heading to Houston: What We're Looking Forward to at ASN Kidney Week 2025 (with Dr. Pietro Canetta)

  Nov 3, 202547 minS0

  <p>Bluestar is once again heading to ASN Kidney Week, this time in Houston, TX. Since our last episode, Otsuka, the manufacturer of sibeprenlimab, announced that the FDA has granted Priority Review of their BLA application; its PDUFA date is November 28th of this year. Additionally, Vera Therapeutics, the manufacturer of atacicept put out a press release this past summer that the ORIGIN Phase 3 trial met its primary endpoint of reduction in proteinuria (UPCR); participants receiving atacicept achieved a 46% reduction from baseline, and 42% reduction compared to placebo at week 36 (p

  ListenShow Notes
• 

  Episode #6

  B-cells vs. Complement in IgAN: A Look at the Data from Kidney Week 2024 (with Dr. Vlado Perkovic)

  Dec 9, 202431 minS0

  <p>Principal Jeff Fineberg, PhD sits down with Vlado Perkovic, MBBS, PhD, to discuss the IgA nephropathy trial data presented at Kidney Week 2024 in San Diego. Jeff begins by asking Dr. Perkovic to talk about why targeting B-cells is an attractive target, and why BAFF/APRIL might prove more promising than CD20. The two then discuss the data with two agents in development for the treatment of IgAN, atacicept (targeting BAFF/APRIL) and sibeprenlimab (targeting APRIL only). The conversation then pivots to the prospect of complement inhibition with FABHALTA® (iptacopan) in IgA nephropathy, including a comparison of the strategy to ta...

  ListenShow Notes
• 

  Episode #5

  It's ASN Kidney Week 2024! Here's What We're Excited About (with Dr. Beatrice Goilav)

  Oct 21, 202418 minS0

  <p>Principal Jeff Fineberg, PhD welcomes back returning guest nephrologist Beatrice Goilav, MD, to discuss the program featured at Kidney Week 2024 in San Diego.</p> <p>Dr. Goilav reflects on what has happened in the field since last year's Kidney Week conference, as well as her hopes for what will be presented at a variety of sessions, including more data in IgA nephropathy, lupus nephritis, and FSGS. She also offers her perspective on the newest advancements with complement inhibitors in glomerular diseases – including approval of FABHALTA® (iptacopan) in IgA nephropathy – as well as recommendations for educational symposia and scientific sessions on the...

  ListenShow Notes
• 

  Episode #4

  ADC Alchemy: A Post-ASCO Discussion

  Jul 24, 202413 minS0

  <p>Bluestar Managing Director Erin Olsen is back from the ASCO conference in Chicago and joins Principal Jeff Fineberg on the podcast again, this time to talk about all things antibody drug conjugates (ADCs) in oncology. </p> <p>Given the number and value of deals in this space over the past couple of years, as well as the 170+ ADCs now in clinical development, Jeff asks Erin to take stock of what we've learned about the potential of these molecules, with all their moving parts, and opine on what lies ahead.</p> <p>Over the course of this brief conversation, Erin a...

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.